Tigecycline versus levofloxacin in hospitalized patients with community-acquired pneumonia: An analysis of risk factors

Open Respiratory Medicine Journal

Volumn 7, Issue 1, 2013, Pages 13-20

  Dartois, Nathalie ^a   Cooper, C Angel ^a   Castaing, Nathalie ^a   Gandjini, Hassan ^a   Sarkozy, Denise ^a  

^a PFIZER INC   (United States)

Author keywords

Community acquired pneumonia; Glycylcycline; Risk factors; Tigecycline

Indexed keywords

LEVOFLOXACIN; TIGECYCLINE;

ALCOHOL ABUSE; ARTICLE; BACTEREMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DIABETES MELLITUS; DRUG EFFICACY; HUMAN; HYPOXEMIA; INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE; LEUKOCYTE COUNT; MENTAL HEALTH; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

EID: 84879144982     PISSN: None     EISSN: 18743064     Source Type: Journal    
DOI: 10.2174/1874306401307010013     Document Type: Article

References (27)

1. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of communityacquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-82.
2. Halm EA, Teirstein AS. Clinical practice. Management of community-acquired pneumonia. N Engl J Med 2002; 347: 2039-45.
3. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-33.
4. File TM Jr. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. Clin Microbiol Infect 2006; 12: 31-41.
5. Lynch JP III, Zhanel GG. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy. Semin Respir Crit Care Med 2005; 26: 575-616.
6. Bradley SF. Staphylococcus aureus pneumonia: emergence of MRSA in the community. Semin Respir Crit Care Med 2005; 26: 643-9.
7. Gil DR, Undurraga PA, Saldías PF, Jiménez PP, Barros MM. Prognostic factors and outcome of community-acquired pneumonia in hospitalized adult patients. Rev Med Chil 2006; 134: 1357-66.
8. Hak E, Bont J, Hoes AW, Verheij TJ. Prognostic factors for serious morbidity and mortality from community-acquired lower respiratory tract infections among the elderly in primary care. Fam Pract 2005; 22: 375-80.
9. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 1996; 275: 134-41.
10. Poe RH, Wahl GW, Qazi R, Kallay MC, Utell MJ, Morrow GR. Predictors of mortality in the immunocompromised patient with pulmonary infiltrates. Arch Intern Med 1986; 146: 1304-8.
11. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50.
12. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-82.
13. Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ. Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther 2006; 4: 9-25.
14. Squires RA, Postier RG. Tigecycline for the treatment of infections due to resistant Gram-positive organisms. Expert Opin Investig Drugs 2006; 15: 155-62.
15. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E, Tigecycline 301 and 306 Study Groups. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41: S354-67.
16. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E, Tigecycline 300 and 305 cSSSI Study Groups. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41: S341-53.
17. File TM Jr, Garau J, Blasi F, et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 2004; 125: 1888-901.
18. Woodhead M, Blasi F, Ewig S, et al. European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-80.
19. Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008; 61: 329-38.
20. van de Garde EM, Souverein PC, van den Bosch JM, Deneer VH, Goettsch WG, Leufkens HG. Prior outpatient antibacterial therapy as prognostic factor for mortality in hospitalized pneumonia patients. Respir Med 2006; 100: 1342-8.
21. Molinos L, Clemente MG, Miranda B, et al. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect 2009; 58: 417-24.
22. Ruiz M, Ewig S, Torres A, et al. Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med 1999; 160: 923-9.
23. Menéndez R, Torres A, Rodríguez de Castro F, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004; 39: 1783-90.
24. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159: 2449-54.
25. McGovern P, Wible M, El-Tahtawy A, Biswas P, Meyer D. Mortality imbalance in the tigecycline phase 3 and 4 clinical trials. In: 40th Annual Congress of the Society of Critical Care Medicine. San Diego, CA, 2011.
26. Wyeth Pharmaceuticals Inc. (2011) Tygacil® [tigecycline] for injection for intravenous use. Full prescribing information. URL http://labeling.pfizer.com/showlabeling.aspx?id=491 [Accessed on July 13 2012].
27. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54.